ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting

    Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis

    Fabrizio De Benedetti1, Hermine Brunner2, Eileen M. Baildam3, Ruben Burgos-Vargas3, Gerd Horneff3, Hans-Iko Huppertz3, Kirsten Minden4, Barry L. Myones2, Karen Onel5, Jianmei Wang6, Kamal N. Bharucha7, Daniel J. Lovell2, Alberto Martini8 and Nicolino Ruperto3, 1IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, 2PRCSG, Cincinnati, OH, 3PRINTO, Genoa, Italy, 4Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, 5Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 6Roche Products Ltd., Welwyn Garden City, United Kingdom, 7Genentech, South San Francisco, CA, 8Pediatria II, Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
  • Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting

    Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus

    Ananta Subedi1, Hong Fang2 and Michelle Petri2, 1Good Samaritan Hospital, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…
  • Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting

    Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population

    Boulos Haraoui1, Algis V Jovaisas2, William G. Bensen3, Rafat Y. Faraawi4, John T. Kelsall5, Sanjay Dixit6, Emmanouil Rampakakis7, John S. Sampalis7, Francois Nantel8, Susan M. Otawa9, Allen J. Lehman9 and May Shawi10, 1Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, 5Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 6McMaster University, Hamilton, ON, Canada, 7JSS Medical Research, Montreal, QC, Canada, 8Janssen Inc., Toronto, ON, Canada, 9Medical Affairs, Janssen Inc., Toronto, ON, Canada, 10Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
  • Abstract Number: 1370 • 2013 ACR/ARHP Annual Meeting

    Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases

    Wieneke van den Hombergh1, Annelies van Ede2, J. Fransen3, Femke BG lamers-Karnebeek3, Saskia Kuipers4 and Matthijs Janssen5, 1Rheumatology, UMC st. Radboud, Nijmegen, Netherlands, 2Rheumatology, UMC st Radboud, Nijmegen, Netherlands, 3Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Microbiology, UMC st Radboud, Nijmegen, Netherlands, 5Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands

     Background/Purpose: Pneumocystis jirovecii is a fungal pathogen that causes pneumonia in immunocompromized hosts. Prednisone is frequently suggested as a risk factor for developing pneumocystis pneumonia (PCP) in patients with rheumatic diseases. If prednisone…
  • Abstract Number: 1276 • 2013 ACR/ARHP Annual Meeting

    Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab

    Alysha Taxter1, Kathleen E. Sullivan2 and Jon Burnham3, 1Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, 2Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rituximab is an anti-CD20 monoclonal antibody increasingly used in immunologic and malignant conditions to deplete B cells. Suppression of humoral immunity after rituximab exposure may…
  • Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting

    Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination

    Yunjun Luo1, Diana L. Johnson2, Ronghui Xu3 and Christina D. Chambers1, 1Pediatrics, University of California, San Diego, La Jolla, CA, 2University of California San Diego Department of Pediatrics, La Jolla, CA, 3Family and Preventive Medicine, University of California, San Diego, La Jolla, CA

    Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
  • Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting

    The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis

    Lucía Silva-Fernández1,2, Mark Lunt3, Audrey S. Low2, Kath D. Watson3, BSRBR Control Centre Consortium2, Deborah P. Symmons2, Kimme L. Hyrich4 and On behalf of the BSRBR5, 1Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 5British Society for Rheumatology, London, United Kingdom

    Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
  • Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting

    Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study

    Zaki AbouZahr1, Andrew Spiegelman2, Maria Cantu3 and Bernard Ng4, 1Baylor College of Medicine, Houston, TX, 2Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, 3Baylor College Of Medicine, Houston, TX, 4Michael E. DeBakey VA Medical Center, Houston, TX

    Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
  • Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting

    Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants

    Candace H. Feldman1, Linda T. Hiraki2, Francisco M. Marty3, Wolfgang C. Winkelmayer4, Jessica M. Franklin5, Daniel H. Solomon6,7, Seoyoung C. Kim8 and Karen H. Costenbader9, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 3Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, 4Division of Nephrology, Stanford University School of Medicine, Stanford, CA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 8Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 9Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
  • Abstract Number: 730 • 2013 ACR/ARHP Annual Meeting

    Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis

    John McKinnon1, Robbie Mailliard2, Dawn McClemens-McBride3, Donald Jones3, Charles Rinaldo Jr.4 and Kathleen Maksimowicz-McKinnon5, 1Infectious Disease, Henry Ford Hospital, Detroit, MI, 2Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, 3Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Infectious Diseases and Microbiology, Pathology, University of Pittsburgh, Pittsburgh, PA, 5Rheumatology, Henry Ford Hospital, Detroit, MI

    Background/Purpose: Reactivation of chronic herpesvirus infections is not uncommon in immunosuppressed patients, including those with granulomatosis with polyangiitis (GPA).  The effects of GPA disease and…
  • Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting

    Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial

    Loic Guillevin1, Christian Pagnoux2, Alexandre Karras3, Chahera Khouatra4, Olivier Aumaître5, Pascal Cohen6, Olivier Decaux7, Hélène Desmurs-Clavel8, Pierre Gobert9, Thomas Quemeneur10, Claire Blanchard-Delaunay11, Pascal Godmer12, Xavier Puechal13, Pierre-Louis Carron14, Pierre-Yves Hatron15, Nicolas Limal16, Mohamed Hamidou17, Francois Maurier18, Thomas Papo19, Matthias Büchler20, Bernard Bonnotte21, Philippe Ravaud22 and Luc Mouthon23, 1Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 2Internal Medicine, Hôpital Cochin, PARIS, France, 3Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4CHU Lyon, Lyon, France, 5Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 7Department of Internal Medicine, Rennes University Hospital, Rennes, France, 8University of Lyon, LYON, France, 9Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 10Internal medicine, CHR de Valenciennes, Valenciennes, France, 11Internal Medicine, Hôpital de Niort, Niort, France, 12Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 13Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 14Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, 15Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 16Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, 17Internal Medicine Department, Nantes University Hospital, Nantes, France, 18HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 19Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 20Nephrology, University Hospital of Tours, TOURS, France, 21Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, 22Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 23Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
  • Abstract Number: 2543 • 2012 ACR/ARHP Annual Meeting

    Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents

    Jeffrey R. Curtis1, Shuo Yang2, Nivedita M. Patkar3, Lang Chen4, Jasvinder A. Singh5, Grant W. Cannon6, Ted R. Mikuls7, Elizabeth S. Delzell8, Kenneth G. Saag9, Monika M. Safford10, Scott DuVall11, Kimberly Alexander12, Pavel Napalkov12, Aaron Kamauu13 and John Baddley14, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, 4Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama, Tuscaloosa, AL, 6Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, 7Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 8Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 9Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, 10Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, 11VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 12Epidemiology, Genentech, Inc., South San Francisco, CA, 13Anolinx, Bountiful, UT, 14Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Risks of hospitalized infections for newer biologic agents have not been well characterized compared to risks for anti-TNF therapy. Purpose: To compare the risk…
  • Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting

    How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study

    Hayato Yamazaki1, Ryoko Sakai1, Ryuji Koike2, Yasunari Miyazaki3, Michi Tanaka1, Toshihiro Nanki1, Kaori Watanabe1, Shinsuke Yasuda4, Takashi Kurita5, Yuko Kaneko6, Yoshiya Tanaka7, Yasuhiko Nishioka8, Yoshinari Takasaki9, Kenji Nagasaka10, Koichi Amano11, Shigeto Tohma12, Makoto Dohi13, Takahiko Sugihara14, Haruhito Sugiyama15, Yasushi Kawaguchi16, Naohiko Inase17, Sae Ochi18, Hiroyuki Hagiyama19, Nobuyuki Miyasaka20 and Masayoshi Harigai21, 1Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, 2Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, 4Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 5Department of Medicine II, Hokkaido University, Sapporo, Japan, 6Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, 7The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 8Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, 9Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 10Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, 11Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 12Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, 13Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 14Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 15Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, 16Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 17Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, 18Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 19Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, 20Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, 21Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…
  • Abstract Number: 2452 • 2012 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis-Associated PTPN22 Modulates Toll-Like Receptor-Mediated, Type 1 Interferon-Dependent Innate Immunoregulation

    Yaya Wang1, Stephanie Stanford2, Wenbo Zhou3, Jennifer L. Auger4, Genhong Cheng5, Amanda Campbell6, Fernanda M. Shoyama1, Henry H. Balfour Jr.7, Andrew C. Chan8, Bryce A. Binstadt4, Nunzio Bottini6 and Erik J. Peterson3, 1Department of Medicine, University of Minnesota, Minneapolis, MN, 2Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3University of Minnesota, Minneapolis, MN, 4Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, 5University of California, Los Angeles, Los Angeles, CA, 6La Jolla Institute for Allergy and Immunology, La Jolla, CA, 7University of Minnesota, Minneapolis, 8Immunology, Genentech Inc, South San Francisco, CA

    Background/Purpose: A coding polymorphism (C1858T) in PTPN22 is strongly associated with risk of Rheumatoid Arthritis (RA) and other autoimmune diseases. PTPN22 encodes Lymphoid Phosphatase (Lyp);…
  • Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting

    Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients

    Pierre Charles1, Antoine Néel2, Nathalie Tieulié3, Arnaud Hot4, Grégory Pugnet5, Olivier Decaux6, Isabelle Marie7, Mehdi Khellaf8, Jean-Emmanuel Kahn9, Alexandre Karras10, Jean-Marc Ziza11, Christophe Deligny12, Colas Tchérakian13 and Loic Guillevin14, 1Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 2Internal Medicine, Nantes University Hospital, Nantes, France, 3CHU Nice, Nice, France, 4Internal Medicine, Edouard Herriot University Hospital, Lyon, France, 5Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 6Department of Internal Medicine, Rennes University Hospital, Rennes, France, 7Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 8Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 9Internal Medicine, Foch Hospital, Suresnes, France, 10Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 11Rheumatology, Croix Saint Simon Hospital, Paris, France, 12Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 13Service de pneumologie, hôpital Foch, Suresnes, France, 14Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…
  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology